INTRODUCTION: In patients with non-small cell lung cancer (NSCLC) who present with multiple pulmonary nodules, it is often difficult to distinguish metastatic disease from synchronous primary lung cancers (SPLC). We sought to evaluate clinical outcomes after stereotactic body radiotherapy (SBRT) alone to synchronous primary lesions. MATERIAL AND METHODS: Patients with synchronous AJCC 8th Edition Stage IA-IIA NSCLC and treated with stereotactic body radiation therapy (SBRT) to all lesions between 2009-2018 were reviewed. SPLC was defined as patients having received two courses of SBRT within 180 days for treatment of separate early stage tumors. In total, 36 patients with 73 lesions were included. Overall survival (OS), progression-free survival (PFS), cumulative incidence of local failure (LF), and regional/distant failure (R/DF) were estimated and compared with a control cohort of solitary early stage NSCLC patients. RESULTS: Median PFS was 38.8 months (95% CI 14.3-not reached [NR]); 3-year PFS rates were 50.6% (35.6-72.1). Median OS was 45.9 months (95% CI: 35.9-NR); 3-year OS was 63.0% (47.4-83.8). Three-year cumulative incidence of LF and R/DF was 6.6% (3.7-13.9) and 35.7% (19.3-52.1), respectively. Patients with SPLC were compared to a control group (n = 272) of patients treated for a solitary early stage NSCLC. There was no statistically significant difference in PFS (p = .91) or OS (p = .43). Evaluation of the patterns of failure showed a trend for worse cumulative incidence of R/DF in SPLC patients as compared to solitary early stage NSCLC (p = .06). CONCLUSION: SBRT alone to multiple lung tumors with SPLC results in comparable PFS, OS, and LF rates to a cohort of patients treated for solitary early stage NSCLC. Those with SPLC had non-significantly higher R/DF. Patients with SPLC should be followed closely for failure and possible salvage therapy.
INTRODUCTION: In patients with non-small cell lung cancer (NSCLC) who present with multiple pulmonary nodules, it is often difficult to distinguish metastatic disease from synchronous primary lung cancers (SPLC). We sought to evaluate clinical outcomes after stereotactic body radiotherapy (SBRT) alone to synchronous primary lesions. MATERIAL AND METHODS: Patients with synchronous AJCC 8th Edition Stage IA-IIA NSCLC and treated with stereotactic body radiation therapy (SBRT) to all lesions between 2009-2018 were reviewed. SPLC was defined as patients having received two courses of SBRT within 180 days for treatment of separate early stage tumors. In total, 36 patients with 73 lesions were included. Overall survival (OS), progression-free survival (PFS), cumulative incidence of local failure (LF), and regional/distant failure (R/DF) were estimated and compared with a control cohort of solitary early stage NSCLC patients. RESULTS: Median PFS was 38.8 months (95% CI 14.3-not reached [NR]); 3-year PFS rates were 50.6% (35.6-72.1). Median OS was 45.9 months (95% CI: 35.9-NR); 3-year OS was 63.0% (47.4-83.8). Three-year cumulative incidence of LF and R/DF was 6.6% (3.7-13.9) and 35.7% (19.3-52.1), respectively. Patients with SPLC were compared to a control group (n = 272) of patients treated for a solitary early stage NSCLC. There was no statistically significant difference in PFS (p = .91) or OS (p = .43). Evaluation of the patterns of failure showed a trend for worse cumulative incidence of R/DF in SPLC patients as compared to solitary early stage NSCLC (p = .06). CONCLUSION: SBRT alone to multiple lung tumors with SPLC results in comparable PFS, OS, and LF rates to a cohort of patients treated for solitary early stage NSCLC. Those with SPLC had non-significantly higher R/DF. Patients with SPLC should be followed closely for failure and possible salvage therapy.
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Gregory M M Videtic; Jessica Donington; Meredith Giuliani; John Heinzerling; Tomer Z Karas; Chris R Kelsey; Brian E Lally; Karen Latzka; Simon S Lo; Drew Moghanaki; Benjamin Movsas; Andreas Rimner; Michael Roach; George Rodrigues; Shervin M Shirvani; Charles B Simone; Robert Timmerman; Megan E Daly Journal: Pract Radiat Oncol Date: 2017-06-05
Authors: Joe Y Chang; Yung-Hsien Liu; Zhengfei Zhu; James W Welsh; Daniel R Gomez; Ritsuko Komaki; Jack A Roth; Stephen G Swisher Journal: Cancer Date: 2013-06-24 Impact factor: 6.860
Authors: Zeina Ayoub; Matthew S Ning; Eric D Brooks; Jingjing Kang; James W Welsh; Aileen Chen; Saumil Gandhi; John V Heymach; Ara A Vaporciyan; Joe Y Chang Journal: Int J Radiat Oncol Biol Phys Date: 2020-02-07 Impact factor: 7.038
Authors: Gregory M M Videtic; Chen Hu; Anurag K Singh; Joe Y Chang; William Parker; Kenneth R Olivier; Steven E Schild; Ritsuko Komaki; James J Urbanic; Robert D Timmerman; Hak Choy Journal: Int J Radiat Oncol Biol Phys Date: 2015-07-17 Impact factor: 7.038
Authors: John T Lucas; Jeffrey G Kuremsky; Mike Soike; William W Hinson; William T Kearns; Carnell J Hampton; A William Blackstock; James Urbanic Journal: Lung Cancer Date: 2014-04-28 Impact factor: 6.081
Authors: Hari B Keshava; Kay See Tan; Joe Dycoco; James Huang; Alison Berkowitz; Dyana Sumner; Amy Devigne; Prasad Adusumilli; Manjit Bains; Matthew Bott; James Isbell; Robert Downey; Daniela Molena; Bernard Park; Gaetano Rocco; Smita Sihag; David R Jones; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2021-11-20 Impact factor: 6.439